Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
Previous Symbol
CUSIPN/A
Phone617-607-0800
Debt
Debt-to-Equity RatioN/A
Current Ratio23.74
Quick Ratio23.74
Price-To-Earnings
Trailing P/E Ratio21.27
Forward P/E Ratio43.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$206.63 million
Price / Sales6.96
Cash Flow$3.8517 per share
Price / Cash Flow19.22
Book Value$20.32 per share
Price / Book3.64
Profitability
EPS (Most Recent Fiscal Year)$3.48
Net Income$71.95 million
Net Margins34.82%
Return on Equity21.56%
Return on Assets20.35%
Miscellaneous
Employees113
Outstanding Shares19,420,000
Market Cap$1.42 billion
OptionableOptionable
Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions
What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
How were Enanta Pharmaceuticals' earnings last quarter?
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its quarterly earnings data on Monday, November, 26th. The biotechnology company reported $1.30 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.24 by $0.06. The biotechnology company earned $67.20 million during the quarter, compared to the consensus estimate of $69.03 million. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. Enanta Pharmaceuticals's quarterly revenue was down 11.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.86 earnings per share. View Enanta Pharmaceuticals' Earnings History.
When is Enanta Pharmaceuticals' next earnings date?
What price target have analysts set for ENTA?
6 brokers have issued 1 year price targets for Enanta Pharmaceuticals' stock. Their predictions range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $108.25 in the next twelve months. This suggests a possible upside of 46.2% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.
What is the consensus analysts' recommendation for Enanta Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.
Has Enanta Pharmaceuticals been receiving favorable news coverage?
News stories about ENTA stock have been trending somewhat positive on Tuesday, InfoTrie reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of 1.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Enanta Pharmaceuticals' key competitors?
Some companies that are related to Enanta Pharmaceuticals include Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH), Emergent Biosolutions (EBS), Horizon Pharma (HZNP) and Array Biopharma (ARRY).
Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the folowing people:
- Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
- Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
- Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
- Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 63)
- Ms. Carol Miceli, Director of Investor Relations
Who are Enanta Pharmaceuticals' major shareholders?
Enanta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.37%), Vanguard Group Inc. (7.36%), Renaissance Technologies LLC (4.38%), First Manhattan Co. (3.60%), Dimensional Fund Advisors LP (3.12%) and Krensavage Asset Management LLC (2.64%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.
Which institutional investors are selling Enanta Pharmaceuticals stock?
ENTA stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Man Group plc, FMR LLC, WINTON GROUP Ltd, Renaissance Technologies LLC, First Trust Advisors LP, Wells Fargo & Company MN and Chicago Equity Partners LLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda, Paul J Mellett and Tim Ocain. View Insider Buying and Selling for Enanta Pharmaceuticals.
Which institutional investors are buying Enanta Pharmaceuticals stock?
ENTA stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Matarin Capital Management LLC, BlackRock Inc., First Manhattan Co., Teachers Advisors LLC, Acadian Asset Management LLC, HL Financial Services LLC and Marshall Wace LLP. View Insider Buying and Selling for Enanta Pharmaceuticals.
How do I buy shares of Enanta Pharmaceuticals?
Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enanta Pharmaceuticals' stock price today?
One share of ENTA stock can currently be purchased for approximately $74.03.
How big of a company is Enanta Pharmaceuticals?
Enanta Pharmaceuticals has a market capitalization of $1.42 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.
What is Enanta Pharmaceuticals' official website?
How can I contact Enanta Pharmaceuticals?
Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]
MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
